Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 945

1.

The association of CMV with NK-cell reconstitution depends on graft source: results from BMT CTN-0201 samples.

Rashidi A, Luo X, Cooley S, Anasetti C, Waller EK, Brunstein CG, Cichocki F, Weisdorf DJ, Miller JS.

Blood Adv. 2019 Aug 27;3(16):2465-2469. doi: 10.1182/bloodadvances.2019000298. No abstract available.

2.

Dinaciclib enhances natural killer cell cytotoxicity against acute myelogenous leukemia.

Yun HD, Schirm DK, Felices M, Miller JS, Eckfeldt CE.

Blood Adv. 2019 Aug 27;3(16):2448-2452. doi: 10.1182/bloodadvances.2019000064. No abstract available.

3.

Factors Influencing the Use of Cognitive-Behavioral Therapy with Autistic Adults: A Survey of Community Mental Health Clinicians.

Maddox BB, Crabbe SR, Fishman JM, Beidas RS, Brookman-Frazee L, Miller JS, Nicolaidis C, Mandell DS.

J Autism Dev Disord. 2019 Aug 5. doi: 10.1007/s10803-019-04156-0. [Epub ahead of print]

PMID:
31385175
4.

Viewpoint: Metalloids-An Electronic Band Structure Perspective.

Miller JS.

Chemistry. 2019 Aug 2. doi: 10.1002/chem.201903167. [Epub ahead of print]

PMID:
31373421
5.

Ten simple rules for giving an effective academic job talk.

Sura SA, Smith LL, Ambrose MR, Amorim CEG, Beichman AC, Gomez ACR, Juhn M, Kandlikar GS, Miller JS, Mooney J, Mummah RO, Lohmueller KE, Lloyd-Smith JO.

PLoS Comput Biol. 2019 Jul 25;15(7):e1007163. doi: 10.1371/journal.pcbi.1007163. eCollection 2019 Jul. No abstract available.

6.

First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia.

Cooley S, He F, Bachanova V, Vercellotti GM, DeFor TE, Curtsinger JM, Robertson P, Grzywacz B, Conlon KC, Waldmann TA, McKenna DH, Blazar BR, Weisdorf DJ, Miller JS.

Blood Adv. 2019 Jul 9;3(13):1970-1980. doi: 10.1182/bloodadvances.2018028332.

7.

Feedback loops in the major evolutionary transition to eusociality: the status and potential of theoretical approaches.

Miller JS, Reeve HK.

Curr Opin Insect Sci. 2019 May 8;34:85-90. doi: 10.1016/j.cois.2019.04.008. [Epub ahead of print] Review.

PMID:
31247424
8.

Chronic stimulation drives human NK cell dysfunction and epigenetic reprograming.

Merino A, Zhang B, Dougherty P, Luo X, Wang J, Blazar BR, Miller JS, Cichocki F.

J Clin Invest. 2019 Jun 18;130. pii: 125916. doi: 10.1172/JCI125916.

9.

Autism spectrum disorder and neurodevelopmental delays in children with giant omphalocele.

Danzer E, Hoffman C, Miller JS, D'Agostino JA, Schindewolf EM, Gerdes M, Bernbaum J, Adams SE, Rintoul NE, Herkert LM, Taylor L, Schreiber J, Peranteau WH, Flake AW, Adzick NS, Hedrick HL.

J Pediatr Surg. 2019 May 28. pii: S0022-3468(19)30384-7. doi: 10.1016/j.jpedsurg.2019.05.017. [Epub ahead of print]

PMID:
31196668
10.

What's in a name? A preliminary event-related potential study of response to name in preschool children with and without autism spectrum disorder.

Thomas RP, Wang LAL, Guthrie W, Cola M, McCleery JP, Pandey J, Schultz RT, Miller JS.

PLoS One. 2019 May 7;14(5):e0216051. doi: 10.1371/journal.pone.0216051. eCollection 2019.

11.

Multivascular networks and functional intravascular topologies within biocompatible hydrogels.

Grigoryan B, Paulsen SJ, Corbett DC, Sazer DW, Fortin CL, Zaita AJ, Greenfield PT, Calafat NJ, Gounley JP, Ta AH, Johansson F, Randles A, Rosenkrantz JE, Louis-Rosenberg JD, Galie PA, Stevens KR, Miller JS.

Science. 2019 May 3;364(6439):458-464. doi: 10.1126/science.aav9750.

PMID:
31048486
12.

Colonization, Baker's law, and the evolution of gynodioecy in Hawaii: implications from a study of Lycium carolinianum.

Miller JS, Blank CM, Levin RA.

Am J Bot. 2019 May;106(5):733-743. doi: 10.1002/ajb2.1279. Epub 2019 May 1.

PMID:
31042317
13.

Setting traps for NKG2A gives NK cell immunotherapy a fighting chance.

Cichocki F, Miller JS.

J Clin Invest. 2019 Apr 15;129(5):1839-1841. doi: 10.1172/JCI128480. eCollection 2019 Apr 15.

14.

Auditory evoked response delays in children with 47,XYY syndrome.

Bloy L, Ku M, Edgar JC, Miller JS, Blaskey L, Ross J, Roberts TPL.

Neuroreport. 2019 May 1;30(7):504-509. doi: 10.1097/WNR.0000000000001233.

PMID:
30896674
15.

A novel ex vivo tumor system identifies Src-mediated invasion and metastasis in mesenchymal tumor cells in non-small cell lung cancer.

Padhye A, Ungewiss C, Fradette JJ, Rodriguez BL, Albritton JL, Miller JS, Gibbons DL.

Sci Rep. 2019 Mar 20;9(1):4819. doi: 10.1038/s41598-019-41301-2.

16.

Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL.

Felices M, Kodal B, Hinderlie P, Kaminski MF, Cooley S, Weisdorf DJ, Vallera DA, Miller JS, Bachanova V.

Blood Adv. 2019 Mar 26;3(6):897-907. doi: 10.1182/bloodadvances.2018029371.

17.

An Observational Study With the Janssen Autism Knowledge Engine (JAKE®) in Individuals With Autism Spectrum Disorder.

Ness SL, Bangerter A, Manyakov NV, Lewin D, Boice M, Skalkin A, Jagannatha S, Chatterjee M, Dawson G, Goodwin MS, Hendren R, Leventhal B, Shic F, Frazier JA, Janvier Y, King BH, Miller JS, Smith CJ, Tobe RH, Pandina G.

Front Neurosci. 2019 Feb 27;13:111. doi: 10.3389/fnins.2019.00111. eCollection 2019.

18.

Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab.

Erbe AK, Wang W, Carmichael L, Hoefges A, Grzywacz B, Reville PK, Ranheim EA, Hank JA, Kim K, Seo S, Mendonca EA, Song Y, Kenkre VP, Hong F, Gascoyne RD, Paietta E, Horning SJ, Miller JS, Kahl B, Sondel PM.

J Immunother Cancer. 2019 Mar 12;7(1):70. doi: 10.1186/s40425-019-0538-8.

19.

Predicted Risk of Mortality Score predicts 30-day readmission after coronary artery bypass grafting.

Rosenblum JM, Lovasik BP, Hunting JC, Binongo J, Halkos ME, Leshnower BG, Miller JS, Lattouf OM, Guyton RA, Keeling WB.

Gen Thorac Cardiovasc Surg. 2019 Aug;67(8):661-668. doi: 10.1007/s11748-019-01079-6. Epub 2019 Feb 8.

PMID:
30734216
20.

Direct observation of the intermediate in an ultrafast isomerization.

Porter TM, Wang J, Li Y, Xiang B, Salsman C, Miller JS, Xiong W, Kubiak CP.

Chem Sci. 2018 Oct 8;10(1):113-117. doi: 10.1039/c8sc03258k. eCollection 2019 Jan 7.

21.

Sperm maturation and male tactic-specific differences in ejaculates in the plainfin midshipman fish Porichthys notatus.

Miller JS, Bose APH, Fitzpatrick JL, Balshine S.

J Fish Biol. 2019 Mar;94(3):434-445. doi: 10.1111/jfb.13912. Epub 2019 Feb 21.

PMID:
30701548
22.

Adaptive NK cell reconstitution is associated with better clinical outcomes.

Cichocki F, Taras E, Chiuppesi F, Wagner JE, Blazar BR, Brunstein C, Luo X, Diamond DJ, Cooley S, Weisdorf DJ, Miller JS.

JCI Insight. 2019 Jan 24;4(2). pii: 125553. doi: 10.1172/jci.insight.125553. [Epub ahead of print]

23.

Assessing Canonical and Adaptive Natural Killer Cell Function in Suppression Assays In Vitro.

Sarhan D, Miller JS.

Methods Mol Biol. 2019;1913:153-166. doi: 10.1007/978-1-4939-8979-9_11.

PMID:
30666605
24.

Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells.

Uppendahl LD, Felices M, Bendzick L, Ryan C, Kodal B, Hinderlie P, Boylan KLM, Skubitz APN, Miller JS, Geller MA.

Gynecol Oncol. 2019 Apr;153(1):149-157. doi: 10.1016/j.ygyno.2019.01.006. Epub 2019 Jan 15.

PMID:
30658847
25.

Monocyte Subpopulation Recovery as Predictors of Hematopoietic Cell Transplantation Outcomes.

Turcotte LM, Cao Q, Cooley SA, Curtsinger J, Holtan SG, Luo X, Yingst A, Weisdorf DJ, Blazar BR, Miller JS, Wagner JE, Verneris MR.

Biol Blood Marrow Transplant. 2019 May;25(5):883-890. doi: 10.1016/j.bbmt.2019.01.003. Epub 2019 Jan 6.

PMID:
30625388
26.

Donor Killer Cell Immunoglobulin-Like Receptor Genotype Does Not Improve Graft-versus-Leukemia Responses in Chronic Lymphocytic Leukemia after Unrelated Donor Transplant: A Center for International Blood and Marrow Transplant Research Analysis.

Bachanova V, Weisdorf DJ, Wang T, Marsh SGE, Cereb N, Haagenson MD, Spellman SR, Lee SJ, Guethlein LA, Parham P, Miller JS, Cooley SA.

Biol Blood Marrow Transplant. 2019 May;25(5):949-954. doi: 10.1016/j.bbmt.2018.12.763. Epub 2018 Dec 27.

PMID:
30594542
27.

Early Indicators of Creatine Transporter Deficiency.

Miller JS, Thomas RP, Bennett A, Bianconi S, Bruchey A, Davis RJ, Ficicioglu C, Guthrie W, Porter FD, Thurm A.

J Pediatr. 2019 Mar;206:283-285. doi: 10.1016/j.jpeds.2018.11.008. Epub 2018 Dec 20.

28.

Anomalous Stoichiometry, 3-D Bridged Triangular/Pentagonal Layered Structured Artificial Antiferromagnet for the Prussian Blue Analogue A3MnII5(CN)13 (A = NMe4, NEtMe3). A Cation Adaptive Structure.

Lapidus SH, Graham AG, Kareis CM, Hawkins CG, Stephens PW, Miller JS.

J Am Chem Soc. 2019 Jan 16;141(2):911-921. doi: 10.1021/jacs.8b10638. Epub 2019 Jan 4.

PMID:
30557002
29.

Natural Killer Cell Homing and Persistence in the Bone Marrow After Adoptive Immunotherapy Correlates With Better Leukemia Control.

Grzywacz B, Moench L, McKenna D Jr, Tessier KM, Bachanova V, Cooley S, Miller JS, Courville EL.

J Immunother. 2019 Feb/Mar;42(2):65-72. doi: 10.1097/CJI.0000000000000250.

PMID:
30489431
30.

Peritoneal NK cells are responsive to IL-15 and percentages are correlated with outcome in advanced ovarian cancer patients.

Hoogstad-van Evert JS, Maas RJ, van der Meer J, Cany J, van der Steen S, Jansen JH, Miller JS, Bekkers R, Hobo W, Massuger L, Dolstra H.

Oncotarget. 2018 Oct 5;9(78):34810-34820. doi: 10.18632/oncotarget.26199. eCollection 2018 Oct 5.

31.

Anomalous Stoichiometry and Antiferromagnetic Ordering for the Extended Hydroxymanganese(II) Cubes/Hexacyanometalate-Based 3D-Structured [MnII 4 (OH)4 ][MnII (CN)6 ](OH2 )6 ⋅H2 O.

Lapidus SH, Stephens PW, Kareis CM, VanNatta PE, Miller JS.

Chemistry. 2019 Feb 1;25(7):1752-1757. doi: 10.1002/chem.201804935. Epub 2019 Jan 8.

PMID:
30286266
32.

Autism Spectrum Disorder and Transition-Aged Youth.

Bennett AE, Miller JS, Stollon N, Prasad R, Blum NJ.

Curr Psychiatry Rep. 2018 Sep 21;20(11):103. doi: 10.1007/s11920-018-0967-y. Review.

PMID:
30238166
33.

Occupational radiation exposure and risk of cataract incidence in a cohort of US radiologic technologists.

Little MP, Kitahara CM, Cahoon EK, Bernier MO, Velazquez-Kronen R, Doody MM, Borrego D, Miller JS, Alexander BH, Simon SL, Preston DL, Hamada N, Linet MS, Meyer C.

Eur J Epidemiol. 2018 Dec;33(12):1179-1191. doi: 10.1007/s10654-018-0435-3. Epub 2018 Aug 27.

PMID:
30151727
34.

Reduced-Intensity Conditioning Followed by Related and Unrelated Allografts for Hematologic Malignancies: Expanded Analysis and Long-Term Follow-Up.

Warlick ED, DeFor TE, Bejanyan N, Holtan S, MacMillan M, Blazar BR, Dusenbery K, Arora M, Bachanova V, Cooley S, Lazaryan A, McGlave P, Miller JS, Rashidi A, Slungaard A, Vercellotti G, Ustun C, Brunsein C, Weisdorf D.

Biol Blood Marrow Transplant. 2019 Jan;25(1):56-62. doi: 10.1016/j.bbmt.2018.07.038. Epub 2018 Aug 1.

PMID:
30077015
35.

ARID5B regulates metabolic programming in human adaptive NK cells.

Cichocki F, Wu CY, Zhang B, Felices M, Tesi B, Tuininga K, Dougherty P, Taras E, Hinderlie P, Blazar BR, Bryceson YT, Miller JS.

J Exp Med. 2018 Sep 3;215(9):2379-2395. doi: 10.1084/jem.20172168. Epub 2018 Jul 30.

36.

Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors.

Margolin K, Morishima C, Velcheti V, Miller JS, Lee SM, Silk AW, Holtan SG, Lacroix AM, Fling SP, Kaiser JC, Egan JO, Jones M, Rhode PR, Rock AD, Cheever MA, Wong HC, Ernstoff MS.

Clin Cancer Res. 2018 Nov 15;24(22):5552-5561. doi: 10.1158/1078-0432.CCR-18-0945. Epub 2018 Jul 25.

PMID:
30045932
37.

Leukaemia and myeloid malignancy among people exposed to low doses (<100 mSv) of ionising radiation during childhood: a pooled analysis of nine historical cohort studies.

Little MP, Wakeford R, Borrego D, French B, Zablotska LB, Adams MJ, Allodji R, de Vathaire F, Lee C, Brenner AV, Miller JS, Campbell D, Pearce MS, Doody MM, Holmberg E, Lundell M, Sadetzki S, Linet MS, Berrington de González A.

Lancet Haematol. 2018 Aug;5(8):e346-e358. doi: 10.1016/S2352-3026(18)30092-9. Epub 2018 Jul 17.

38.

Current strategies exploiting NK-cell therapy to treat haematologic malignancies.

Johnson JK, Miller JS.

Int J Immunogenet. 2018 Jul 16. doi: 10.1111/iji.12387. [Epub ahead of print] Review.

PMID:
30009514
39.

HVAD: The ENDURANCE Supplemental Trial.

Milano CA, Rogers JG, Tatooles AJ, Bhat G, Slaughter MS, Birks EJ, Mokadam NA, Mahr C, Miller JS, Markham DW, Jeevanandam V, Uriel N, Aaronson KD, Vassiliades TA, Pagani FD; ENDURANCE Investigators.

JACC Heart Fail. 2018 Sep;6(9):792-802. doi: 10.1016/j.jchf.2018.05.012. Epub 2018 Jul 11.

40.

Occupational radiation exposure and glaucoma and macular degeneration in the US radiologic technologists.

Little MP, Kitahara CM, Cahoon EK, Bernier MO, Velazquez-Kronen R, Doody MM, Borrego D, Miller JS, Alexander BH, Simon SL, Preston DL, Meyer C, Linet MS, Hamada N.

Sci Rep. 2018 Jul 11;8(1):10481. doi: 10.1038/s41598-018-28620-6.

41.

Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells.

Yun HD, Felices M, Vallera DA, Hinderlie P, Cooley S, Arock M, Gotlib J, Ustun C, Miller JS.

Blood Adv. 2018 Jul 10;2(13):1580-1584. doi: 10.1182/bloodadvances.2018018176. No abstract available.

42.

161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS.

Sarhan D, Brandt L, Felices M, Guldevall K, Lenvik T, Hinderlie P, Curtsinger J, Warlick E, Spellman SR, Blazar BR, Weisdorf DJ, Cooley S, Vallera DA, Önfelt B, Miller JS.

Blood Adv. 2018 Jun 26;2(12):1459-1469. doi: 10.1182/bloodadvances.2017012369.

43.

Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma.

Domingo-Musibay E, Murugan P, Giubellino A, Sharma S, Steinberger D, Yuan J, Hunt MA, Lou E, Miller JS.

J Immunother Cancer. 2018 Jun 19;6(1):58. doi: 10.1186/s40425-018-0357-3.

44.

Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37.

Sarhan D, Hippen KL, Lemire A, Hying S, Luo X, Lenvik T, Curtsinger J, Davis Z, Zhang B, Cooley S, Cichocki F, Blazar BR, Miller JS.

Cancer Immunol Res. 2018 Jul;6(7):766-775. doi: 10.1158/2326-6066.CIR-17-0498. Epub 2018 May 21.

45.

Absence of early HHV-6 reactivation after cord blood allograft predicts powerful graft-versus-tumor effect.

Rashidi A, Ebadi M, Said B, Cao Q, Shanley R, Curtsinger J, Bejanyan N, Warlick ED, Green JS, Brunstein CG, Miller JS, Weisdorf DJ.

Am J Hematol. 2018 May 14. doi: 10.1002/ajh.25141. [Epub ahead of print]

46.

Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice.

Pennell CA, Barnum JL, McDonald-Hyman CS, Panoskaltsis-Mortari A, Riddle MJ, Xiong Z, Loschi M, Thangavelu G, Campbell HM, Storlie MD, Refaeli Y, Furlan SN, Jensen MC, Kean LS, Miller JS, Tolar J, Osborn MJ, Blazar BR.

Mol Ther. 2018 Jun 6;26(6):1423-1434. doi: 10.1016/j.ymthe.2018.04.006. Epub 2018 Apr 7.

47.

Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD.

Bejanyan N, Brunstein CG, Cao Q, Lazaryan A, Luo X, Curtsinger J, Mehta RS, Warlick E, Cooley SA, Blazar BR, Miller JS, Weisdorf D, Wagner JE, Verneris MR.

Blood Adv. 2018 Apr 24;2(8):909-922. doi: 10.1182/bloodadvances.2017014464.

48.

ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.

Wrangle JM, Velcheti V, Patel MR, Garrett-Mayer E, Hill EG, Ravenel JG, Miller JS, Farhad M, Anderton K, Lindsey K, Taffaro-Neskey M, Sherman C, Suriano S, Swiderska-Syn M, Sion A, Harris J, Edwards AR, Rytlewski JA, Sanders CM, Yusko EC, Robinson MD, Krieg C, Redmond WL, Egan JO, Rhode PR, Jeng EK, Rock AD, Wong HC, Rubinstein MP.

Lancet Oncol. 2018 May;19(5):694-704. doi: 10.1016/S1470-2045(18)30148-7. Epub 2018 Apr 5.

49.

Interleukin-15 Complex Treatment Protects Mice from Cerebral Malaria by Inducing Interleukin-10-Producing Natural Killer Cells.

Burrack KS, Huggins MA, Taras E, Dougherty P, Henzler CM, Yang R, Alter S, Jeng EK, Wong HC, Felices M, Cichocki F, Miller JS, Hart GT, Johnson AJ, Jameson SC, Hamilton SE.

Immunity. 2018 Apr 17;48(4):760-772.e4. doi: 10.1016/j.immuni.2018.03.012. Epub 2018 Apr 3.

50.

A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia.

Fehniger TA, Miller JS, Stuart RK, Cooley S, Salhotra A, Curtsinger J, Westervelt P, DiPersio JF, Hillman TM, Silver N, Szarek M, Gorelik L, Lowdell MW, Rowinsky E.

Biol Blood Marrow Transplant. 2018 Aug;24(8):1581-1589. doi: 10.1016/j.bbmt.2018.03.019. Epub 2018 Mar 27.

Supplemental Content

Loading ...
Support Center